Content area
Full Text
MADRID, September 10, 2010 /PRNewswire/ --
- Fast Track status is granted to facilitate development and expedite the review of a drug for a serious or potentially fatal illness and to meet an unmet medical need.
- The Phase II trial for Progressive Supranuclear Palsy (PSP) commenced in December 2009 and is currently in progress.
- Belen Sopesen, CEO of Noscira: "Fast Track status is very positive for the company and is an incentive to continue advancing in the clinical development of Tideglusib (ZentylorTM) in Progressive Supranuclear Palsy."
Noscira, a Grupo Zeltia (ZEL.MC) subsidiary specialised in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder. A Phase II trial with Tideglusib (ZentylorTM) in PSP commenced in December 2009 and is currently in progress.
The FDA grants Fast Track status to facilitate the development and expedite the review of a drug to treat serious and potentially fatal diseases and to fill an unmet medical...